Fred Hutchinson Cancer Research Center immunobioengineer Dr. Matthias Stephan has received a 2018 Investigator’s Award in Cell and Gene Therapy for Cancer from the Alliance for Cancer Gene Therapy to support the development of a combined T-cell programming, cancer-vaccine strategy to treat cancer. His proposed method, which unites nanoparticles that carry cancer vaccine–specific T-cell receptor genes with a vaccine designed to trigger an immune response to a patient’s tumor, aims to improve the effectiveness of therapeutic cancer vaccines by guaranteeing that the patient has cancer-specific T cells capable of responding to the vaccine.
